{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:31:35Z","timestamp":1771515095802,"version":"3.50.1"},"reference-count":31,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Antiseizure medications (ASMs) are the second most widely prescribed psychotropic for people with intellectual disabilities in England. Multiple psychotropic prescribing is prevalent in almost half of people with intellectual disabilities on ASMs. This analysis identifies limited evidence of ASM benefit in challenging behaviour management and suggests improvements needed to inform clinical practice.<\/jats:p>","DOI":"10.1192\/bjp.2022.182","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:31:53Z","timestamp":1676367113000},"page":"191-195","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":18,"title":["Antiseizure medications prescribing for behavioural and psychiatric concerns in adults with an intellectual disability living in England"],"prefix":"10.1192","volume":"222","author":[{"given":"David","family":"Branford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-6933","authenticated-orcid":false,"given":"Rohit","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"S0007125022001829_ref21","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13612"},{"key":"S0007125022001829_ref1","volume-title":"British National Formulary 78 ed","year":"2019"},{"key":"S0007125022001829_ref25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14656566.2019.1695780","article-title":"Quality improvement in the management of people with epilepsy and intellectual disability: the development of clinical guidance","volume":"21","author":"Watkins","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"S0007125022001829_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.05.022"},{"key":"S0007125022001829_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108191"},{"key":"S0007125022001829_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.03.011"},{"key":"S0007125022001829_ref18","unstructured":"18 LeDeR. Learning Disabilities Mortality Review: Annual Report 2020. Bristol University, 2021 (https:\/\/leder.nhs.uk\/images\/annual_reports\/LeDeR-bristol-annual-report-2020.pdf)."},{"key":"S0007125022001829_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.11.001"},{"key":"S0007125022001829_ref30","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.34"},{"key":"S0007125022001829_ref13","volume-title":"Prescribing of Psychotropic Drugs to People with Learning Disabilities and\/or Autism by General Practitioners in England. Technical Report","author":"Glover","year":"2015"},{"key":"S0007125022001829_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108355"},{"key":"S0007125022001829_ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.55"},{"key":"S0007125022001829_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.08.039"},{"key":"S0007125022001829_ref16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2788.2007.00965.x","article-title":"The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: a systematic review","volume":"52","author":"Deb","year":"2008","journal-title":"J Intellect Disabil Res"},{"key":"S0007125022001829_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2011.06.007"},{"key":"S0007125022001829_ref23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1684\/epd.2021.1366","article-title":"Epilepsy in adults with neurodevelopmental disability - what every neurologist should know","volume":"2","author":"Watkins","year":"2022","journal-title":"Epileptic Disord"},{"key":"S0007125022001829_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.05.004"},{"key":"S0007125022001829_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7511.2005.00056.x"},{"key":"S0007125022001829_ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2018.12"},{"key":"S0007125022001829_ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ph3092986"},{"key":"S0007125022001829_ref5","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.1\/hcrgrunze"},{"key":"S0007125022001829_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10938-3"},{"key":"S0007125022001829_ref31","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2011.13.2\/npatsopoulos"},{"key":"S0007125022001829_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.16.1981"},{"key":"S0007125022001829_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2015.03.016"},{"key":"S0007125022001829_ref12","volume-title":"Health and Care of People with Learning Disabilities Experimental Statistics 2020 to 2021"},{"key":"S0007125022001829_ref3","article-title":"Are anti-seizure medications over-prescribed in people with intellectual disability","author":"Branford","year":"2022","journal-title":"Research Gate"},{"key":"S0007125022001829_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.07.018"},{"key":"S0007125022001829_ref11","article-title":"Psychotropic Drugs and People with Learning Disabilities or Autism. Technical Report","author":"Mehta","year":"2019","journal-title":"Public Health England,"},{"key":"S0007125022001829_ref22","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp22X720077"},{"key":"S0007125022001829_ref24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324660"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125022001829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T21:34:27Z","timestamp":1701898467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125022001829\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0007125022001829"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2022.182","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}